{"DataElement":{"publicId":"7412476","version":"1","preferredName":"Medical History Domain Children's Oncology Group Acute Lymphoblastic Leukemia Therapeutic Procedure Receive Name","preferredDefinition":"An indication of the specific COG ALL frontline study patient was treated according to.","longName":"SUPPMH_QVAL_MHCOGTX_ALL_NM","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7412464","version":"1","preferredName":"Medical History Domain Children's Oncology Group Acute Lymphoblastic Leukemia Therapeutic Procedure Receive","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject medical history._An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers._Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._To take, accept, or get something offered.","longName":"6401571v1.0:7412462v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6401571","version":"1","preferredName":"Medical History Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject medical history.","longName":"C49603","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medical History Domain","conceptCode":"C49603","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject medical history.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"738FDBAB-92FD-1DB7-E053-F662850A27F3","latestVersionIndicator":"Yes","beginDate":"2018-08-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-16","modifiedBy":"ONEDATA","dateModified":"2018-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7412462","version":"1","preferredName":"Children's Oncology Group Acute Lymphoblastic Leukemia Therapeutic Procedure Receive","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:To take, accept, or get something offered.","longName":"C39353:C3167:C49236:C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6BDE05-D373-7B88-E053-4EBD850A32E3","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6BDE05-D384-7B88-E053-4EBD850A32E3","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"SETRAKIN","dateModified":"2020-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7412471","version":"1","preferredName":"COG ALL frontline therapeutic trial Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"7412471v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BDF6-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL1732","valueDescription":"AALL1732","ValueMeaning":{"publicId":"7412472","version":"1","preferredName":"COG AALL1732","longName":"7412472v1.00","preferredDefinition":"COG NCT03959085","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE00-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE19-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL1731","valueDescription":"AALL1731","ValueMeaning":{"publicId":"7412473","version":"1","preferredName":"AALL1731","longName":"7412473","preferredDefinition":"AALL1731","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE23-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE3C-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL1131","valueDescription":"AALL1131","ValueMeaning":{"publicId":"7412474","version":"1","preferredName":"AALL1131","longName":"7412474","preferredDefinition":"AALL1131","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE46-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE5F-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL0932","valueDescription":"AALL0932","ValueMeaning":{"publicId":"7412475","version":"1","preferredName":"AALL0932","longName":"7412475","preferredDefinition":"AALL0932","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE69-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE82-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL0631","valueDescription":"AALL0631","ValueMeaning":{"publicId":"6334902","version":"1","preferredName":"AALL0631","longName":"6334902","preferredDefinition":"AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431, NSC#617807)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB4F-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE8C-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL0331","valueDescription":"AALL0331","ValueMeaning":{"publicId":"4626600","version":"1","preferredName":"AALL0331","longName":"4626600","preferredDefinition":"AALL0331","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09BB4635-4386-5E75-E050-BB89AD4329AC","latestVersionIndicator":"Yes","beginDate":"2014-12-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-12-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BE96-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL0232","valueDescription":"AALL0232","ValueMeaning":{"publicId":"4626602","version":"1","preferredName":"AALL0232","longName":"4626602","preferredDefinition":"AALL0232","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09BB4635-43CC-5E75-E050-BB89AD4329AC","latestVersionIndicator":"Yes","beginDate":"2014-12-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-12-08","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE6CBDDA-BEA0-27C9-E053-4EBD850A692A","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"AALL2321","valueDescription":null,"ValueMeaning":{"publicId":"12983683","version":"1","preferredName":"AALL2321","longName":"12983683v1.00","preferredDefinition":"AALL2321","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63C89B5-DF0A-2475-E053-731AD00A1C88","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63C89B5-DF0B-2475-E053-731AD00A1C88","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"AALL15P1","valueDescription":null,"ValueMeaning":{"publicId":"6289553","version":"1","preferredName":"AALL15P1","longName":"6289553","preferredDefinition":"AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C47CDEE-2533-28DE-E053-F662850A6987","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63C89B5-DF0C-2475-E053-731AD00A1C88","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BDDF-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please indicate which study:","type":"Preferred Question Text","description":"Please indicate which study:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Please indicate which study patient was treated according to:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CCAAB-D045-330C-E053-4EBD850AEE1D","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":"2023.3.6 AQT added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"}}